Market closedNon-fractional

Annexon/ANNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Annexon

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Ticker

ANNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Brisbane, United States

Employees

70

Annexon Metrics

BasicAdvanced
$505M
Market cap
-
P/E ratio
-$1.37
EPS
1.29
Beta
-
Dividend rate
$505M
1.29
20.615
20.174
10.873
11.732
-28.60%
-50.60%
1.66
1.66
-3.614
-39.94%
-24.35%

What the Analysts think about Annexon

Analyst Ratings

Majority rating from 8 analysts.
Buy

Annexon Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
-9.71%
Profit margin
0.00%
NaN%

Annexon Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 38.47%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.43
-$0.36
-$0.21
-
Expected
-$0.54
-$0.50
-$0.44
-$0.34
-$0.23
Surprise
-13.56%
-14.47%
-17.34%
-38.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Annexon stock?

Annexon (ANNX) has a market cap of $505M as of July 05, 2024.

What is the P/E ratio for Annexon stock?

The price to earnings (P/E) ratio for Annexon (ANNX) stock is 0 as of July 05, 2024.

Does Annexon stock pay dividends?

No, Annexon (ANNX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Annexon dividend payment date?

Annexon (ANNX) stock does not pay dividends to its shareholders.

What is the beta indicator for Annexon?

Annexon (ANNX) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Annexon stock

Buy or sell Annexon stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing